Insurer Seeks to Overturn Ruling on Cancer Coverage
The company filed a motion in Miami court to stop paying for a $48,500 drug therapy following a prior court-ordered mandate.
Updated on Oct. 30, 2026 in Cancer
Miami resident Pablo Langesfeld, who is fighting stage four pancreatic cancer, faces a new legal hurdle as Oscar Insurance Company moves to overturn a previous court victory. A judge and jury previously ordered the insurer to cover his treatment, but the company is now seeking to vacate that ruling.
Why it matters
The case highlights the ongoing struggle for patients seeking coverage for complex cancer therapies as the court decides whether insurance companies can retroactively challenge approved claims. The outcome will clarify if the company must provide the court-ordered medication or if the patient's enrollment in an experimental trial impacts their obligation.
The drug therapy in question costs $48,500 every three weeks. A judicial ruling on the insurance company's request to overturn the previous coverage mandate is expected within four or five weeks.
The players
Pablo Langesfeld
A Miami resident currently battling stage four pancreatic cancer who is involved in a legal dispute over medical coverage.
Oscar Insurance Company
The health insurance provider currently seeking to overturn a court ruling requiring it to cover medication for a policyholder.
Migna Sanchez-Llorens
The judge presiding over the case who issued a previous ruling in favor of the patient.
The details
Oscar Insurance Company argues that Langesfeld failing to take the specific drug combination constitutes newly discovered evidence, justifying a request to vacate the earlier court victory. Langesfeld originally sued after the insurer denied the medication in December 2025, leading to a favorable jury and judicial ruling in the spring of 2026. The insurer's attorneys presented their arguments in a Miami courtroom on October 30, 2026.
Timeline
December 2025: Oscar Insurance Company denied coverage for the medication.
April 2026: A jury ruled in favor of Langesfeld.
May 2026: Judge Migna Sanchez-Llorens issued a ruling for Langesfeld.
October 30, 2026: Oscar attorneys appeared in court for a hearing.
Late November or early December 2026: The judge is expected to issue a new ruling.
Beyond the 305
This dispute marks a departure from the 2026 court ruling in favor of Pablo Langesfeld that originally mandated insurance coverage for his treatment. The new motion tests whether an insurer can retroactively revoke an obligation to provide high-cost therapies based on a patient's alternative care choices.
Residents currently navigating complex health insurance denials should watch this case to see how the court treats patient alternatives like experimental drug trials. The final ruling will determine if the insurer remains liable for the $48,500 medication costs moving forward.
The takeaway
Patients currently fighting for coverage should monitor this case to understand how insurance companies may attempt to challenge previous court orders. Keep track of the expected judicial ruling anticipated by early December 2026.
What happens next
The judge is expected to issue a ruling on the motion to overturn the previous decision by late November or early December 2026.
Further reading
For more updates on medical insurance disputes and patient rights, visit the Cancer section.
Source note: This article includes information reported by NBC 6 South Florida.
